ERBB4 and idiopathic pulmonary fibrosis: Collectively, these results suggest that ERBB4 and SYK are attractive targets for IPF treatment; however, further preclinical studies are needed to confirm the suppression of lung fibrosis following the inhibition of the expression and activation of these kinases.